References
- Gaynes R. The impact of antimicrobial use on the emer-gence of antimicrobial-resistant bacteria in hospitals. Infect Dis Clin North Am 1997; 11 (4): 757–765.
- Davey P. Pharmacoeconomics of appropriate antimicro-bial use. Diagn Microbiol Infect Dis 1995; 22 (1-2): 225–229.
- Sáez-Llorens X, Castrejón de Wong MM, Castatio E, De Suman 0, De Morös D, De Atencio I. Impact of an antibiotic re-striction policy on hospital expenditures and bacterial suscepti-bilities: a lesson from a pediatric institution in a developing country. Pediatr Infect Dis J 2000; 19 (3): 200–206.
- Giamarellou H, Touliatou K, Koratzanis G, Petrikkos G, Kanellakopoulou K, Lelekis M, et al. Nosocomial consequences of antibiotic usage. Scand J Infect Dis Suppl 1986; 49: 182–188.
- Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280 (14): 1233–1237.
- Giamarellou H, Antoniadou A. The effect of monitoring of antibiotic use on decreasing antibiotic resistance in the hospital. Ciba Found Symp 1997; 207: 76–86. Review
- Ito W, Kobayashi N, Kayaba H, Takahashi T, Takeda M, Chiba T, et al. Clinical evaluation after an introduction of our manual for antibiotic use during perioperative period and a noti-fication policy of use of the antibiotics for MRSA. Rinsho Byori 2007; 55 (3): 224–229. Japanese.
- Kohno S, Yamaguchi K, Aikawa N, Sumiyama Y, Odagiri S, Aoki N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus au-reus in Japan. J Antimicrob Chemother 2007; 60 (6): 1361–1369.
- Fukuda Y, Yanagihara K, Nakamura S, Otsu Y, Kaneko Y, Miyazaki Y, et al. Successful treatment with linezolid in two cases of methicillin-resistant Staphylococcus aureus infections in the orthopedic field. Kansenshogaku Zasshi 2003; 77 (8): 622–626. Japanese.
- Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Eu-rope: a report from the SENTRY antimicrobial surveillance pro-gram. Diagn Microbiol Infect Dis 2007; 58 (2): 163–170.
- Peeters MJ, Sarria JC. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am J Med Sci. 2005; 330 (2): 102–104.
- Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombo-cytopenia associated with linezolid therapy. Clin Infect Dis. 2002; 34 (5): 695–698.
- Plachouras D, Giannitsioti E, Athanassia S, Kontopidou F, Papadopoulos A, Kanellakopoulou K,et al. No effect of pyri-doxine on the incidence of myelosuppression during prolonged linezolid treatment. Clin Infect Dis. 2006; 43 (9): e89–91.
- Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, et al. Hematologic effects of linezolid: summary of clin-ical experience. Antimicrob Agents Chemother 2002; 46 (8): 2723–2726.
- Garazzino S, De Rosa FG, Bargiacchi 0, Audagnotto S, Maiello A, Di Perri G. Haematological safety of long-term ther-apy with linezolid. Int J Antimicrob Agents 2007; 29 (4): 480–483.
- Bishop E, Melvani S, Howden BP, Charles PG, Grayson ML. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed proto-col for monitoring therapy in complex patients. Antimicrob Agents Chemother 2006; 50 (4): 1599–1602.
- Ziglam HM, Elliott I, Wilson V, Hill K, Nathwani D. Clini-cal audit of linezolid use in a large teaching hospital. J Antimicrob Chemother 2005; 56 (2): 423–426.